Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

527 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter study of leukocytapheresis in rheumatoid arthritis.
Ueki Y, Sagawa A, Tanimura K, Yamada A, Yamamoto K, Tsuda H, Tohma S, Suzuki K, Tominaga M, Kawabe Y, Mine M, Honda S, Tsukano M, Nakamura T, Hidaka T, Eguchi K. Ueki Y, et al. Among authors: kawabe y. Clin Exp Rheumatol. 2007 Nov-Dec;25(6):810-6. Clin Exp Rheumatol. 2007. PMID: 18173913
Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
Iwamoto N, Kawakami A, Fujikawa K, Aramaki T, Kawashiri SY, Tamai M, Arima K, Ichinose K, Kamachi M, Yamasaki S, Nakamura H, Nakashima M, Mizokami A, Goto A, Fukuda T, Matsuoka N, Ueki Y, Tsukada T, Migita K, Shoumura F, Kawabe Y, Shibatomi K, Mine M, Ida H, Origuchi T, Aoyagi K, Eguchi K. Iwamoto N, et al. Among authors: kawabe y. Mod Rheumatol. 2009;19(5):488-92. doi: 10.1007/s10165-009-0187-8. Epub 2009 Jul 4. Mod Rheumatol. 2009. PMID: 19578932
Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor.
Origuchi T, Iwamoto N, Kawashiri SY, Fujikawa K, Aramaki T, Tamai M, Arima K, Nakamura H, Yamasaki S, Ida H, Kawakami A, Ueki Y, Matsuoka N, Nakashima M, Mizokami A, Kawabe Y, Mine M, Fukuda T, Eguchi K. Origuchi T, et al. Among authors: kawabe y. Mod Rheumatol. 2011 Jun;21(3):244-50. doi: 10.1007/s10165-010-0384-5. Epub 2010 Dec 29. Mod Rheumatol. 2011. PMID: 21188454
Clinical outcomes in the first year of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome.
Origuchi T, Arima K, Umeda M, Kawashiri SY, Tamai M, Nakamura H, Tsukada T, Miyashita T, Iwanaga N, Izumi Y, Furuyama M, Tanaka F, Kawabe Y, Aramaki T, Ueki Y, Eguchi K, Fukuda T, Kawakami A. Origuchi T, et al. Among authors: kawabe y. Mod Rheumatol. 2017 Jan;27(1):150-154. doi: 10.1080/14397595.2016.1192744. Epub 2016 Jun 20. Mod Rheumatol. 2017. PMID: 27320419
Expression of membrane-type 1 matrix metalloproteinase in rheumatoid synovial cells.
Honda S, Migita K, Hirai Y, Origuchi T, Yamasaki S, Kamachi M, Shibatomi K, Fukuda T, Kita M, Hida A, Ida H, Aoyagi T, Kawakami A, Kawabe Y, Oizumi K, Eguchi K. Honda S, et al. Among authors: kawabe y. Clin Exp Immunol. 2001 Oct;126(1):131-6. doi: 10.1046/j.1365-2249.2001.01624.x. Clin Exp Immunol. 2001. PMID: 11678909 Free PMC article.
Clinical significance of anti-citrullinated peptide antibody in Japanese patients with established rheumatoid arthritis.
Nakamura H, Kawakami A, Ida H, Origuchi T, Matsuoka N, Tsuboi M, Furuyama M, Mizokami A, Tsukada T, Nakashima M, Ejima E, Hamasaki K, Aoyagi K, Uetani M, Fukuda T, Honda S, Urayama S, Kawabe Y, Ueki Y, Mine M, Eguchi K. Nakamura H, et al. Among authors: kawabe y. Scand J Rheumatol. 2005 Nov-Dec;34(6):489-90. doi: 10.1080/03009740510026706. Scand J Rheumatol. 2005. PMID: 16393775 No abstract available.
527 results